Families of patients with frontotemporal dementia living in the community face many challenges. Access to quality care, effective treatment modalities, and short or long-term placements are several of the challenges. Early recognition, family education, and appropriate specialist referral can lessen the burden for families as they navigate the health system during this progressive disease.
Introduction
This case illustrates the challenges involved in management of the community-dwelling, older adult with frontotemporal dementia (FTD) with worsening behaviors. CR was a 62 year-old Caucasian male who had a medical necessity to be seen in the home by a nurse practitioner (NP). The initial NP encounters focused on assessment of the family's report of his behaviors and direct observation of CRs interactions with the environment. Follow up care included ongoing education and interventions to address specific behavioral problems including apathy, reduced empathy, sleep disturbances, repetitive and obsessive behaviors, and aggression.
Case history

Subjective
At the time of the initial NP visit, CR had not seen a health care provider for over one year due to the family's inability to safely transport him to appointments secondary to cognitive decline. CR had been diagnosed with frontotemporal dementia (FTD) at age 58 by a neurologist. Initially, he exhibited classic behaviors including anomia and impaired meanings of words, but minimal memory impairment. Per the family report, the symptoms had worsened over the past year to include repetitive clucking, loss of empathy, and increased apathy. His sleep pattern was normal, though he had experienced insomnia and nighttime agitation in the past. He was continent of bowel and bladder though increased agitation was noted when he experienced the urge to defecate. Socially, CR lived on a family farm with his spouse of 40 years and three adult children living nearby. Spouse and family were very supportive, and the shared goal was to manage the patient's symptoms at home with outside caregiver support as needed so that he could "die where he was born". CR had a third-party payer insurance and did not qualify for age-related services in the county of residence. CR's neurologist-initiated medications included quetiapine 50 mg and trazodone 100 mg at night for the previous two years.
Objective
During the initial six months, CR was pleasant and interactive, and speech was pressured with constant word production and not appropriate to conversation. He demonstrated the ability to feed himself and ambulate without assistance. Cognitively he did not recognize any family or friends and was unable to participate with dementia screenings. Other physical exam elements were essentially normal.
Assessment
Following an evaluation of past personality, behavioral, and cognitive history and unremarkable physical examination, it was clear that this patient had language dysfunction consistent with primary progressive aphasia, semantic variant (svPPA). The spouse and family knowledge of disease type and progression was minimal at the time of the initial NP encounter.
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Plan
Extensive education of spouse and family on FTD disease type, expected progression, and limited pharmacological treatment was completed at monthly house call visits. Quetiapine and trazodone were continued since patient was stable and adverse reactions were minimal.
End-stage disease progression
Approximately seven months after the initial NP encounter, CR became incontinent, aggressive, and began experiencing visual and auditory hallucinations over a two-week period. He was exhibiting fear, paranoia, increased agitation with personal care, and insomnia. A comprehensive exam and diagnostic testing including CBC, CMP, and urinalysis reflected no acute medical issues. Over a month, medication adjustments included adding valproic acid for labile mood and increasing quetiapine dose for hallucinations. Spouse and family were not getting sleep, and the patient's behaviors were escalating.
CR refused to travel in a vehicle limiting outpatient neurology evaluations. Over the next 45 days, the family's frustration increased with inconsistent navigation through the health care system related to lack of information and treatment options for FTD. CR was admitted to a geriatric inpatient assessment center for two weeks and returned home on the same medication except valproic acid was replaced with gabapentin. After three days at home, CR's behaviors worsened with increased agitation and aggression including destruction of property, physical aggression, and persistent insomnia. Spouse, family, and caregivers were unable to mitigate behaviors in the home environment. CR was taken to the emergency department (ED) and subsequently transferred to a residential nursing home (NH). After two days at the NH, the patient was asked to leave since behaviors (wandering, agitation, and aggression) were not controlled. CR was transferred to the ED and then admitted to an inpatient mental health center for two weeks. Following treatment at the outpatient center with trazodone, gabapentin, and quetiapine, CR was admitted to an inpatient memory care unit, and he died a short time later. This case study illustrates the impact of worsening of behaviors with FTD, lack of pharmacological treatment options, and pitfalls of navigation through the existing healthcare system.
Frontotemporal dementia presentation
Frontotemporal dementia (FTD) is a neurogenerative disease with clinical syndromes and frontal and/or temporal lobe pathology.
1 Classic presentation of FTD includes a focal syndrome with either aphasia or conduct disturbance. 2 FTD often affects younger persons, ultimately causing a psychological and financial burden to families, especially due to young age of diagnosis and subsequent disability. 1, 3, 4 Primary progressive aphasia and behavioral variant frontotemporal dementia are clinical variants of frontotemporal dementia. 4, 5, 6 The estimated prevalence is 15-22/100,000, and annual incidence is 2.7-4.1/100,000. 2 The non-Caucasian population is underrepresented in these statistics. CR was diagnosed with FTD by neurologist with no mention of clinical subtypes. Initial discussion by the nurse practitioner with the family further defined this diagnosis as svPPA subtype and prognosis. The sudden onset of behavioral decline and associated decreased ability to manage him at home prompted the NP to identify additional treatment options so that CR could remain in the home with family.
Pharmacological treatment
Currently there are no psychopharmacologic agents to halt FTD progression and limited class I evidence for behavioral symptom treatment. 7, 8 Pharmacologic treatment of patients with FTD is typically aimed at symptom management. Some common drug classes historically used include N-methyl D-aspartate glutamate (NMDA) receptor antagonists, acetylcholinesterase inhibitors, selective serotonin reuptake inhibitors (SSRIs), antidepressants, mood stabilizers, and neuroleptic/antipsychotic agents. 9 Acetylcholinesterase inhibitors and NMDA receptor antagonists
Acetylcholinesterase inhibitors, such as donepezil, are widely used in treatment of Alzheimer's Dementia (AD); as many with FTD may have been misdiagnosed initially with AD they may have been placed on these medications at some point. However, as there is no specific cholinergic deficiency with FTD, acetylcholinesterase inhibitors are viewed as having limited benefit and in some cases may actually worsen behaviors in FTD. 10 For many with FTD, NMDA receptor antagonists, such as memantine, have been anecdotally reported to have some benefit, but studies have failed to demonstrate efficacy.
11,12
Antidepressants The SSRI's, such as paroxetine or citalopram, are often employed in attempts to mitigate the obsessive behaviors in FTD with some success though studies have demonstrated mixed effects including worsened cognition. 13, 14 Trazodone, a tetracyclic antidepressant, has been shown to reduce irritability, sleep disturbance, depressive symptoms and obsessive eating behaviors seen in FTD. 15 
Mood stabilizers
Mood stabilizing agents, such as gabapentin, do not have an FDA approved indication for behaviors associated with dementia but are commonly prescribed off-label to control behavioral disturbances. 16 However, the lack of randomized control studies dictate the use of these agents in treatment of behavioral disturbances attributable to dementia be considered investigational and off-label.
Neuroleptics
The contemporary neuroleptic agents, such as risperidone and quetiapine, have anecdotal positive effects on the repetitive and obsessive behaviors of FTD. The potential for extrapyramidal side effects and increased somnolence known to be associated with these drugs suggest conservative use for this indication. 8 Both the typical and atypical antipsychotic agents have been associated with increased mortality when used to treat behavioral disorders in elderly patients with dementia. The FDA requires that these drugs carry its strongest "black box" warning on their labels. The examination into specific causes of death related to the atypical agents based on placebo-controlled studies revealed that most were due to cardiovascular-related events (e.g. heart failure, sudden cardiac death) or infections (e.g. pneumonia). 17 The increased risk of death related to the typical antipsychotic agents was based on observational studies and has not been clearly defined. The existing studies regarding pharmacologic treatment strategies for FLD are few and outdated. In light of the limited pharmacologic options, management and treatment for FTD patients are focused on attentive listening to and education for caregivers, coordination of care for respite hospitalizations for violent or increasingly aggressive behaviors as needed, and adapting the environment to the patient throughout this progressive disease.
18,8
Frustration with health system navigation The burden of early recognition of FTD often falls to the primary care provider. This early identification can facilitate appropriate family education, specialist referral, and help manage expectations of disease course and treatment. The early onset of FTD often poses unique challenges in the way of employment issues and legal difficulties resulting from the behavioral changes associated with FTD. Also of particular concern is the lack of appropriate short or long-term placements for these patients as many long-term care facilities are reluctant to accept these patients who are typically younger and exhibit aggressive, difficult to manage behaviors.
Conclusion
The NP caring for the deteriorating FTD patient and family must be able to provide ongoing education and support as well as facilitate navigation of the health system throughout this progressive disease. The complex nature of this disease in relationship to patient outcomes, family legal and financial resources, and clinician treatment expectations requires specialized NP knowledge. Understanding of the progressive nature of the disease, appropriate pharmacologic and social interventions, and the high risk for family/caregiver burden can optimize outcomes, ensure family expectations are managed, and preserve the patients' quality of life as this disease progresses.
